The role of cystatin C and the angiogenic cytokines VEGF and bFGF in patients with esophageal carcinoma

Medical Oncology

Volumn 22, Issue 1, 2005, Pages 29-38

  Dreilich, Martin ^a   Wagenius, Gunnar ^a   Bergström, Stefan ^a   Brattström, Daniel ^a   Larsson, Anders ^a   Hesselius, Patrik ^a   Bergqvist, Michael ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

bFGF; Cystatin C; Esophageal carcinoma; Survival; VEGF

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CREATININE; CYSTATIN C; VASCULOTROPIN;

ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; TUMOR VOLUME;

EID: 18444379095     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/mo:22:1:029     Document Type: Article

References (34)

1. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
3. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002;9:36-44.
4. Koide N, et al. Histochemical study of vascular endothelial growth factor in squamous cell carcinoma of the esophagus. Hepatogastroenterology 1999;46:952-958.
5. Li Z, et al. TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol 2000;17:453-460.
6. Nakagawa S, Nishimaki T, Suzuki T, Kanda T, Kuwabara S, Hatakeyama K. Tumor angiogenesis as an independent prognostic factor after extended radical esophagectomy for invasive squamous cell carcinoma of the esophagus. Surgery 2001;129:302-308.
7. Ogata Y, Fujita H, Yamana H, Sueyoshi S, Shirouzu K. Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study. World J Surg 2003;27:584-589.
8. Klagsbrun M, D'Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996;7:259-270.
9. Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 2002;200:581-597.
10. Shimada H, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001;92:663-669.
11. Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol 2003;43:309-319.
12. Barrett AJ, et al. Nomenclature and classification of the proteins homologous with the cysteine-proteinase inhibitor chicken cystatin. Biochem J 1986;236:312.
13. Saitoh E, et al. The human cystatin C gene (CST3) is a member of the cystatin gene family which is localized on chromosome 20. Biochem Biophys Res Commun 1989;162:1324-1331.
14. Stabuc B, Vrhovec L, Stabuc-Silih M, Cizej TE. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 2000;46:193-197.
15. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221-226.
16. Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta 2000;300:83-95.
17. Kos J, et al. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 1998;44:2556-2557.
18. Nagai A, et al. Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin Chim Acta 2003;329:53-60.
19. Zubrod G, Schneiderman M, Frei EI. Appraisal of methods for the study of chemotherapy of cancer in man: comperative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 1960;11:733.
20. Dietz A, Rudat V, Conradt C, Weidauer H, Ho A, Moehler T. Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy. Head Neck 2000;22:666-673.
21. Davies MM, Jonas SK, Kaur S, Allen-Mersh TG. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume. Br J Cancer 2000;82:1004-1008.
22. Brattstrom D, et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 2002;37:57-63.
23. Spence GM, et al. Vascular endothelial growth factor levels in serum and plasma following esophageal cancer resection-relationship to platelet count. Int J Biol Markers 2002;17:119-124.
24. Akerblom B, Lindahl TL, Larsson A. ADP activation induces bFGF binding to platelets in vitro. Ups J Med Sci 2002;107:165-171.
25. Elpek GO, et al. The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J Clin Pathol 2001;54:940-944.
26. Finney H, Williams AH, Price CP. Serum cystatin C in patients with myeloma. Clin Chim Acta 2001;309:1-6.
27. Caldwell RB, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442-455.
28. Asselbergs FW, et al. Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria? Int J Cardiol 2004;93:211-215.
29. George ML, Tutton MG, Abulafi AM, Eccles SA, Swift RI. Plasma basic fibroblast growth factor levels in colorectal cancer: a clinically useful assay? Clin Exp Metastasis 2002;19:735-738.
30. Karayiannakis AJ, et al. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 2002;131:548-555.
31. Kido Y. Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer. Kurume Med J 2001;48:43-47.
32. Ueno K, Inoue Y, Kawaguchi T, Hosoe S, Kawahara M. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 2001;31:213-219.
33. Arii S, Mori A, Uchida S, Fujimoto K, Shimada Y, Imamura M. Implication of vascular endothelial growth factor in the development and metastasis of human cancers. Hum Cell 1999;12:25-30.
34. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001;47:617-623.